feburic用法与用量
feburic (febuxostat, febuxostat) is a xanthine oxidase (XO) inhibitor indicated for the long-term treatment of hyperuricemia with gout symptoms. Not recommended for the treatment of asymptomatic hyperuricemia.
feburic was approved for marketing in the United States in 2009. Its main ingredient is febuxostat in tablet form. From the development and use of the first gout acid-lowering drug to today, treatment options for gout patients have been continuously developed and increased. Feburic is a safe and effective drug for the treatment of gout, and diet does not affect its acid-lowering effect.
feburic usage and dosage:
Usually, the initial recommended dose of feburic (febuxostat, febuxostat) for patients is 40 mg/day, taken orally. If the symptoms are severe, it can be adjusted to 80 mg/day; if the serum uric acid level is still higher than 6 mg/dL after taking 40 mg/day for 2 weeks, the dose can be increased to 80 mg/day.
Dose adjustment: Patients with mild to moderate (CrCl 30-89 mL/min) renal impairment do not need to adjust the dose; patients with severe (CrCl <30 mL/min) dosage should not exceed 40 mg/day. No dose adjustment is required for patients with mild to moderate (Child-Pugh Class A or B) hepatic impairment; there are no trial data for patients with severe (Child-Pugh Class C) hepatic impairment and should be used with caution.
Use in Special Populations: The safety and effectiveness of feburic in patients under 18 years of age have not been established. Elderly patients do not need to adjust the dosage, but it cannot be ruled out that some elderly patients are more sensitive to this product. Breastfeeding women should use feburic with caution. Because studies on rats have found that feburic can be excreted in breast milk, but it is not yet known whether it is excreted in human milk. Because many medications can be excreted in breast milk, patients should be cautious to avoid harm to the baby.
The usage and dosage of feburic (febuxostat, febuxostat) should be strictly in accordance with the doctor's instructions. If the patient has special circumstances or suffers from other diseases, the doctor should be informed in advance.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)